- Home
- INTC vs GILD Comparison
INTC vs GILD Comparison
Compare INTC & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTC | GILD |
|---|---|---|
| Founded | 1968 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.7B | 187.5B |
| IPO Year | 2007 | 2000 |
Fundamental Metrics
Financial Performance| Metric | INTC | GILD |
|---|---|---|
| Price | $44.05 | $146.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 32 | 18 |
| Target Price | $43.60 | ★ $143.50 |
| AVG Volume (30 Days) | ★ 66.5M | 6.5M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | ★ 2.22% |
| EPS Growth | 98.63 | ★ 1684.21 |
| EPS | N/A | ★ 6.78 |
| Revenue | ★ $52,853,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $3.96 | $4.68 |
| Revenue Next Year | $7.63 | $5.81 |
| P/E Ratio | ★ N/A | $21.82 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $17.67 | $95.30 |
| 52 Week High | $54.60 | $157.29 |
Technical Indicators
Market Signals| Indicator | INTC | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 51.55 |
| Support Level | $42.68 | $108.90 |
| Resistance Level | $46.97 | $157.29 |
| Average True Range (ATR) | 1.88 | 3.64 |
| MACD | -0.44 | -1.39 |
| Stochastic Oscillator | 19.76 | 23.38 |
Price Performance
Historical ComparisonAbout INTC Intel Corporation
Intel is a leading digital chipmaker focused on designing and manufacturing microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and led the semiconductor industry down the path of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. The company is seeking to reinvigorate its chip manufacturing business, Intel Foundry, while developing leading-edge products in its Intel Products business segment.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).